Lantern Pharma Inc. (LTRN)Healthcare | Biotechnology | Dallas, United States | NasdaqCM
3.46 USD
-0.14
(-3.889%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:09 a.m. EDT
Lantern Pharma presents a stark dichotomy between a distressed balance sheet and a speculative clinical pipeline. Fundamentally, the company is in severe trouble: it has posted four consecutive years of negative annual returns, with the stock down 71% over the last five years. The business is burning cash aggressively, with negative free cash flow and a return on equity of -157%. Despite a high analyst target price, this reflects a binary bet on a potential cure rather than sustainable earnings power; the current valuation is detached from reality given the lack of profitability. The short-term outlook remains bearish due to the relentless downward trend and the heavy concentration of options activity in protective puts. Speculators are clearly pricing in further volatility and downside risk, not a near-term recovery. The recent news of a registered direct offering suggests the company is raising capital to survive, which often signals liquidity constraints rather than growth acceleration. While the oncology AI and orphan drug recognition headlines offer a narrative hook for a turnaround, the financials tell a story of erosion. This is a high-risk speculative vehicle where the odds favor the downside until a definitive clinical milestone changes the fundamental equation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.308147 |
| AutoETS | 0.325056 |
| AutoTheta | 0.333733 |
| AutoARIMA | 0.352046 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 5.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.037 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.714 |
| Market Cap | 44,146,644 |
| Forward P/E | -1.71 |
| Beta | 2.29 |
| Website | https://www.lanternpharma.com |
As of July 11, 2026, 3:09 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed significantly toward bearish bets, with deep strikes showing high volume and open interest. While there is some speculative call activity at near-term strikes, the overwhelming capital allocation is in hedging against further declines rather than betting on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.097744346 |
| Address1 | 1,920 McKinney Avenue |
| Address2 | 7th Floor |
| All Time High | 24.84 |
| All Time Low | 1.11 |
| Ask | 3.48 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 198,810 |
| Average Daily Volume3 Month | 257,781 |
| Average Volume | 257,781 |
| Average Volume10Days | 198,810 |
| Beta | 2.294 |
| Bid | 3.5 |
| Bid Size | 1 |
| Book Value | 0.306 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.46 |
| Current Ratio | 1.868 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.645 |
| Day Low | 3.46 |
| Debt To Equity | 1.714 |
| Display Name | Lantern Pharma |
| Earnings Call Timestamp End | 1,774,902,600 |
| Earnings Call Timestamp Start | 1,774,902,600 |
| Earnings Timestamp | 1,778,875,200 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -16,593,150 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.98 |
| Enterprise Value | 32,850,474 |
| Eps Current Year | -1.51 |
| Eps Forward | -2.02 |
| Eps Trailing Twelve Months | -1.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3102 |
| Fifty Day Average Change | 0.14980006 |
| Fifty Day Average Change Percent | 0.04525408 |
| Fifty Two Week Change Percent | -9.774435 |
| Fifty Two Week High | 5.744 |
| Fifty Two Week High Change | -2.284 |
| Fifty Two Week High Change Percent | -0.3976323 |
| Fifty Two Week Low | 1.11 |
| Fifty Two Week Low Change | 2.35 |
| Fifty Two Week Low Change Percent | 2.117117 |
| Fifty Two Week Range | 1.11 - 5.744 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,591,882,200,000 |
| Float Shares | 9,587,400 |
| Forward Eps | -2.02 |
| Forward P E | -1.7128713 |
| Free Cashflow | -8,990,283 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1715 |
| Held Percent Institutions | 0.14156 |
| Implied Shares Outstanding | 12,759,146 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas. |
| Long Name | Lantern Pharma Inc. |
| Market | us_market |
| Market Cap | 44,146,644 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_271124062 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -15,911,826 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 44,146,645 |
| Number Of Analyst Opinions | 2 |
| Open | 3.54 |
| Operating Cashflow | -15,073,997 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 277 1136 |
| Pre Market Change | 0.07999992 |
| Pre Market Change Percent | 2.3121364 |
| Pre Market Price | 3.54 |
| Pre Market Time | 1,784,016,019 |
| Previous Close | 3.6 |
| Price Eps Current Year | -2.2913907 |
| Price Hint | 4 |
| Price To Book | 11.30719 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.682 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -3.88889 |
| Regular Market Day High | 3.645 |
| Regular Market Day Low | 3.46 |
| Regular Market Day Range | 3.46 - 3.645 |
| Regular Market Open | 3.54 |
| Regular Market Previous Close | 3.6 |
| Regular Market Price | 3.46 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 133,751 |
| Return On Assets | -0.73314005 |
| Return On Equity | -1.5737 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,759,146 |
| Shares Percent Shares Out | 0.0728 |
| Shares Short | 929,051 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,477,549 |
| Short Name | Lantern Pharma Inc. |
| Short Percent Of Float | 0.0731 |
| Short Ratio | 4.45 |
| Source Interval | 15 |
| State | TX |
| Symbol | LTRN |
| Target High Price | 25.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 20.0 |
| Target Median Price | 20.0 |
| Total Cash | 6,322,853 |
| Total Cash Per Share | 0.559 |
| Total Debt | 59,076 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.212095 |
| Two Hundred Day Average Change | 0.24790502 |
| Two Hundred Day Average Change Percent | 0.077178605 |
| Type Disp | Equity |
| Volume | 133,751 |
| Website | https://www.lanternpharma.com |
| Zip | 75,201 |